Physician profile
Latoya Smith
NPI 1194208231
$3,368.21
in general payments reported to CMS, 2019-2025
24 companies · $1,719 in 2025
The $1,719 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $225 · 2022: $167 · 2023: $683 · 2024: $575 · 2025: $1,719.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,976.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,976.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,042.43 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $349.16 | 2021-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $313.04 | 2021-2025 | Caplyta |
| Ucb, INC. | $275.41 | 2023-2025 | Briviact, Nayzilam |
| Supernus Pharmaceuticals, INC. | $180.32 | 2025 | Qelbree |
| Sk Life Science, INC. | $160.29 | 2023-2025 | |
| Otsuka America Pharmaceutical, INC. | $132.84 | 2024-2025 | Rexulti |
| Tris Pharma INC | $86.94 | 2024-2025 | Dyanavel Xr |
| Argenx US, INC. | $79.15 | 2024-2025 | Vyvgart Hytrulo |
| Pfizer INC. | $71.57 | 2025 | |
| Indivior INC. | $68.59 | 2023-2025 | Sublocade |
| Biogen, INC. | $67.28 | 2024-2025 | Vumerity, Skyclarys |
| Collegium Pharmaceutical, INC. | $66.56 | 2025 | Jornay Pm |
| Lundbeck LLC | $65.96 | 2021-2025 | Rexulti |
| Alexion Pharmaceuticals, INC. | $65.18 | 2023-2025 | Ultomiris |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $62.32 | 2025 | Fanapt |
| Corium, LLC | $58.69 | 2023-2025 | Azstarys |
| Ironshore Pharmaceuticals INC. | $45.88 | 2023-2024 | Jornay Pm |
| Novo Nordisk INC | $37.10 | 2021 | |
| Amneal Pharmaceuticals LLC | $33.57 | 2025 | Crexont |
| Teva Pharmaceuticals USA, INC. | $33.31 | 2022-2024 | Ajovy |
| Genentech USA, INC. | $28.55 | 2025 | Ocrevus Zunovo |
| Idorsia Pharmaceuticals US INC | $22.29 | 2023 | Quviviq |
| Axsome Therapeutics, INC. | $21.78 | 2025 | Auvelity |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Latoya Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.